Anti-obesity combination therapy of enavogliflozin and low-dose liraglutide

MX2026008042APending Publication Date: 2026-10-02DAEWOONG PHARM CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MX2026008042
Authority / Receiving Office
MX · MX
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-12-27
Filing Date
2026-06-25
Publication Date
2026-10-02
Patent Text Reader

Abstract

The present invention provides an obesity treatment therapy with reduced side effects through co-administration of enavogliflozin and low-dose liraglutide. The combination therapy of enavogliflozin and low dose liraglutide provides a synergistic effect in the treatment of obesity compared to the administration of each drug alone. In addition, the administration dose of liraglutide can be reduced compared to the administration of liraglutide alone, thereby reducing the liraglutide-associated direct cause of side effects related to the gastrointestinal and cardiovascular systems. In addition, the present invention has an advantage of additionally providing an effect of alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through the combination with enavogliflozin.
Need to check novelty before this filing date? Find Prior Art